The Competition Commission of India (CCI) has approved Berhyanda Ltd’s acquisition of up to 76.10% in Suven Pharmaceuticals.

The acquisition is “by way of a share purchase agreement of December 26, 2022 and pursuant to the mandatory open offer in compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011”, the competition regulator said in a statement.

Suven Pharmaceuticals exports active pharmaceutical ingredients and advanced drug intermediates, apart from offering certain services to global pharmaceutical and agrochemical majors.